
	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2025	2026	2025	2026
Share-based compensation expense	$10.9	$10.2	$21.7	$17.1
Tax benefit	0.9	1.0	2.0	2.1

As of December 31, 2025, the Company had unrecognized share-based compensation expense of $70.2 million. As of

June 30, 2026, the Company had unrecognized share-based compensation expense of $62.7 million, which will be recognized

over a weighted average period of approximately three years (assuming no forfeitures).

The following table summarizes transactions in the Company’s restricted stock units:


	Restricted Stock Units	Weighted Average Grant Date Value Per Unit
Unvested units, as of December 31, 2025	1.0	$161.80
Units granted	0.1	299.16
Units vested	(0.2)	153.92
Units forfeited	(0.1)	170.83
Performance condition changes	—	—
Unvested units, as of June 30, 2026	0.8	$180.57

For the six months ended June 30, 2025 and 2026, the Company granted restricted stock units with fair values of $53.8

million and $28.9 million, respectively. These restricted stock units were valued based on the closing price of the Company’s

common stock on the grant date and the number of shares expected to vest. Restricted stock units containing vesting conditions

generally require service over a period of three years to four years and may also require the satisfaction of certain performance

conditions. For awards with performance conditions, the number of restricted stock units expected to vest may change over


	Stock Options	Weighted Average Exercise Price Per Option	Weighted Average Remaining Contractual Life (Years)
Unexercised options outstanding, as of December 31, 2025	0.3	$92.73
Options granted	—	—
Options exercised	(0.2)	81.26
Options forfeited	—	—
Options expired	—	—
Performance condition changes	—	—
Unexercised options outstanding, as of June 30, 2026	0.1	$124.63	2.4
Exercisable at June 30, 2026	0.0	$101.05	1.1

The Company did not grant any stock options during the six months ended June 30, 2025 and 2026. Stock options

generally vest over a period of four years to five years and expire seven years after the grant date. All stock options have been

granted with exercise prices equal to the closing price of the Company’s common stock on the grant date. Substantially all of

the Company’s outstanding stock options contain both service and performance conditions. For awards with performance

conditions, the number of stock options expected to vest may change over time depending upon the performance level expected